Eli Lilly (LLY) financials
Eli Lilly revenue and earnings by year
Eli Lilly's revenue was $65.2 billion in the fiscal year to December 31, 2025, up 44.7% from the year before. Net income was $20.6 billion, 31.7% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 13.3% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 65.2 | 45.0 | 34.1 | 28.5 | 28.3 | 24.5 | 22.3 | 21.5 | 20.0 | 21.2 |
| Revenue growth | 44.7% | 32.0% | 19.6% | 0.8% | 15.4% | 9.9% | 3.8% | 7.6% | -5.9% | — |
| Gross profit | 54.1 | 36.6 | 27.0 | 21.9 | 21.0 | 19.1 | 17.6 | 16.8 | 15.5 | 15.5 |
| Gross margin | 83.0% | 81.3% | 79.2% | 76.8% | 74.2% | 77.7% | 78.8% | 78.2% | 77.7% | 73.1% |
| Operating income | 26.3 | 12.9 | 6.5 | 6.8 | 6.2 | 7.2 | 5.3 | 3.7 | 2.3 | 3.4 |
| Operating margin | 40.4% | 28.6% | 18.9% | 23.8% | 21.7% | 29.5% | 23.6% | 17.1% | 11.5% | 15.9% |
| Net income | 20.6 | 10.6 | 5.2 | 6.2 | 5.6 | 6.2 | 8.3 | 3.2 | -0.2 | 2.7 |
| Net margin | 31.7% | 23.5% | 15.4% | 21.9% | 19.7% | 25.2% | 37.3% | 15.0% | -1.0% | 12.9% |
| Diluted EPS | $22.95 | $11.71 | $5.80 | $6.90 | $6.12 | $6.79 | $8.76 | $3.13 | -$0.20 | $2.58 |
| Free cash flow | 9.0 | 3.8 | 0.8 | 5.7 | 6.1 | 5.1 | 3.8 | 4.3 | 4.5 | 3.9 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open LLY in Markets.
See also: LLY valuation and P/E history · LLY returns
No forecast, no recommendation. This page describes Eli Lilly from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.